Clovis Oncology Inc
Change company Symbol lookup
Select an option...
CLVS Clovis Oncology Inc
BKR Baker Hughes Co
ORC Orchid Island Capital Inc
ORAN Orange SA
OKE ONEOK Inc
OHI Omega Healthcare Investors Inc
OGE OGE Energy Corp
ODFL Old Dominion Freight Line Inc
O Realty Income Corp
NYMT New York Mortgage Trust Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Premarket

Last Trade
Delayed
$5.45
0.03 (0.55%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$5.42
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
2

10-day average volume:
4,428,593
2

Latest Earnings (Q2 ending 06/2020)

Q2
-$1.15
Q2 Consensus estimate
-$1.04

Latest Earnings Estimate Range

Highest
estimate
-$0.83
Mean
estimate
-$1.04
Lowest
estimate
-$1.20

Quarterly Consensus Estimates and Ranges

CLVS's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.